reported a failure to generate a spontaneous anti-tumor immunologic response in the RIP-Tag5 pancreatic neuroendocrine tumor model after CD5-2 treatment, despite normalizing tumor vasculature. This evidence concerns the gene CD5 and pancreatic neuroendocrine tumor.